Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Equivalence of MammaPrint array types in clinical trials and diagnostics.
Beumer I, Witteveen A, Delahaye L, Wehkamp D, Snel M, Dreezen C, Zheng J, Floore A, Brink G, Chan B, Linn S, Bernards R, van 't Veer L, Glas A. Beumer I, et al. Among authors: brink g. Breast Cancer Res Treat. 2016 Apr;156(2):279-87. doi: 10.1007/s10549-016-3764-5. Epub 2016 Mar 22. Breast Cancer Res Treat. 2016. PMID: 27002507 Free PMC article.
Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial.
Jacob L, Witteveen A, Beumer I, Delahaye L, Wehkamp D, van den Akker J, Snel M, Chan B, Floore A, Bakx N, Brink G, Poncet C, Bogaerts J, Delorenzi M, Piccart M, Rutgers E, Cardoso F, Speed T, van 't Veer L, Glas A. Jacob L, et al. Among authors: brink g. Commun Biol. 2020 Jul 27;3(1):397. doi: 10.1038/s42003-020-1111-1. Commun Biol. 2020. PMID: 32719399 Free PMC article.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Bueno-de-Mesquita JM, et al. Among authors: brink g. Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Lancet Oncol. 2007. PMID: 18042430
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van der Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG, Van 't Veer LJ. Ligtenberg MJ, et al. Among authors: brink g. Br J Cancer. 1999 Mar;79(9-10):1475-8. doi: 10.1038/sj.bjc.6690235. Br J Cancer. 1999. PMID: 10188893 Free PMC article.
A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.
Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, Hogervorst F, Brohet R, Ligtenberg MJ, Teugels E, van der Luijt R, van der Hout AH, Gille JJ, Pals G, Jedema I, Olmer R, van Leeuwen I, Newman B, Plandsoen M, van der Est M, Brink G, Hageman S, Arts PJ, Bakker MM, Devilee P, et al. Peelen T, et al. Among authors: brink g. Am J Hum Genet. 1997 May;60(5):1041-9. Am J Hum Genet. 1997. PMID: 9150151 Free PMC article.
315 results